Epimmune Inc.

The University of Chicago

Infectious Disease Research Institute

Pharmexa Inc.

Paxvax, Inc.

Jeffery L Alexander

Mark Joseph Newman

Scott Southwood

Steven G Reed

Alessandro D Sette

Federico C Gaeta

John Sidney

Howard M Grey

Rima McLeod

Kamal El Bissati

Ernest J Mui

Tze Guan Tan

Hua Cong

Florence Dal Degan

William H Witola

Pamuk A Bilsel

Mark J Newman

The present invention provides novel artificial oligopeptides capable of binding HLA Class II molecules encoded by several alleles. The oligopeptides include the sequence AXFVAAXTLXAXA (SEQ ID NO:1), wherein Xis H; Xis selected from the group consisting of F, N, Y and W; Xis H and Xis selected from the group consisting of A, D and E. The invention also relates to large peptides comprising the oligopeptides, polynucleotides encoding the oligopeptides and larger peptides, as well as to compositions comprising the oligopeptides, peptides or polynucleotides. Also disclosed are methods for inducing immune responses.

PAN-DR binding polypeptides and uses thereof

The present invention provides polynucleotides and polypeptides capable of enhancing the immune response of a human in need of protection against influenza virus infection by administering in vivo, into a tissue of the human, at least one polynucleotide comprising one or more regions of nucleic acid encoding an influenza protein or a fragment, variant, or derivative thereof, or at least one polypeptide encoded therefrom. The present invention also relates to identifying and preparing influenza virus epitopes and to polynucleotides and polypeptides comprising such influenza virus epitopes. The present invention also relates to compositions and methods of use in the prevention and treatment of influenza virus infection.

Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions

Vaccines are disclosed against parasites. The vaccines include peptides in an immunological composition. In particular, the parasite is

[object Object]

The present invention provides novel artificial oligopeptides capable of binding HLA Class II molecules encoded by several alleles. The oligopeptides include the sequence AXFVAAXTLXAXA (SEQ ID NO:1), wherein Xis selected from the group consisting of W, F, Y, H, D, E, N, Q, I and K; Xis selected from the group consisting of F, N, Y and W; Xis selected from the group consisting of H and K, and Xis selected from the group consisting of A, D and E, with the proviso that the oligopeptide sequence is not AKFVAAWTLKAAA. The invention also relates to larger peptides comprising the oligopeptides, polynucleotides encoding the oligopeptides and larger peptides, as well as to compositions comprising the oligopeptides, peptides or polynucleotides. Also disclosed are methods for inducing immune responses.

Pan-DR binding polypeptides and uses thereof

The present invention provides compositions and methods of inhibiting or inducing activation of T cells in a patient. The methods comprise administering a therapeutically effective dose of pharmaceutical compositions comprising a pharmaceutically acceptable carrier and peptides of between about 4 and about 20 residues, that bind antigen binding sites on MHC molecules encoded by substantially all alleles of a DR locus. These peptides are referred to as pan DR binding peptides. The pan DR binding peptides can be used to inhibit immune responses associated with immunopathologies, such as autoimmunity, allograft rejection and allergic responses. The peptides can also be used in combination with CTL peptides to enhance a CTL response.

Alteration of immune response using pan DR-binding peptides

Growing community of inventors

San Diego, CA, United States of America

Jeffery L Alexander